Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
JBM (Healthcare) Ltd. ( (HK:2161) ) has issued an announcement.
JBM (Healthcare) Ltd. has entered into a 2025 License Agreement with Europharm, a subsidiary of Jacobson Pharma Corporation Limited, to use a portion of a factory for three years starting from January 2025. This agreement, involving a monthly license fee of HK$218,000, is classified as a connected transaction under Hong Kong’s Listing Rules, requiring reporting and announcement but exempt from circular and independent shareholders’ approval due to its financial scale.
More about JBM (Healthcare) Ltd.
YTD Price Performance: -0.53%
Average Trading Volume: 2,072,054
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$1.55B
For a thorough assessment of 2161 stock, go to TipRanks’ Stock Analysis page.